ZENAS BIOPHARMA INC (ZBIO) Stock Price, Quote, News and Overview
NASDAQ:ZBIO - Nasdaq - US98937L1052 - Common Stock - Currency: USD
ZBIO Quote, Performance and Key Statistics
9.09
-0.65 (-6.67%)
The current stock price of ZBIO is 9.09 USD. In the past month the price increased by 6.94%.
ZBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.57B | ||
| AMGN | AMGEN INC | 13.03 | 145.41B | ||
| GILD | GILEAD SCIENCES INC | 13.1 | 126.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.96 | 61.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.71B | ||
| ARGX | ARGENX SE - ADR | 92.41 | 33.12B | ||
| ONC | BEIGENE LTD-ADR | 5.58 | 24.22B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.72B | ||
| NTRA | NATERA INC | N/A | 20.70B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.28B | ||
| BIIB | BIOGEN INC | 7.79 | 18.05B |
Related stock screener links
About ZBIO
Company Profile
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2024-09-13. The firm's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The firm is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
Company Info
ZENAS BIOPHARMA INC
1000 Winter St, Suite 1200
Waltham MASSACHUSETTS US
Employees: 130
Phone: 18572712954
ZENAS BIOPHARMA INC / ZBIO FAQ
What is the stock price of ZENAS BIOPHARMA INC today?
The current stock price of ZBIO is 9.09 USD. The price decreased by -6.67% in the last trading session.
What is the ticker symbol for ZENAS BIOPHARMA INC stock?
The exchange symbol of ZENAS BIOPHARMA INC is ZBIO and it is listed on the Nasdaq exchange.
On which exchange is ZBIO stock listed?
ZBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZENAS BIOPHARMA INC stock?
13 analysts have analysed ZBIO and the average price target is 32.93 USD. This implies a price increase of 262.28% is expected in the next year compared to the current price of 9.09. Check the ZENAS BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZENAS BIOPHARMA INC worth?
ZENAS BIOPHARMA INC (ZBIO) has a market capitalization of 380.23M USD. This makes ZBIO a Small Cap stock.
How many employees does ZENAS BIOPHARMA INC have?
ZENAS BIOPHARMA INC (ZBIO) currently has 130 employees.
What are the support and resistance levels for ZENAS BIOPHARMA INC (ZBIO) stock?
ZENAS BIOPHARMA INC (ZBIO) has a support level at 9.17 and a resistance level at 9.75. Check the full technical report for a detailed analysis of ZBIO support and resistance levels.
Should I buy ZENAS BIOPHARMA INC (ZBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZBIO, evaluating the profitability, health, valuation and growth aspects
- ZENAS BIOPHARMA INC (ZBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZENAS BIOPHARMA INC (ZBIO) Sales and EPS estimates to see what analysts future expectations are.
- ZENAS BIOPHARMA INC (ZBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZENAS BIOPHARMA INC (ZBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZENAS BIOPHARMA INC (ZBIO) Stock Chart to make your own analysis
- ZENAS BIOPHARMA INC (ZBIO) Latest news and press-releases to stay up to date.
Does ZENAS BIOPHARMA INC (ZBIO) stock pay dividends?
ZBIO does not pay a dividend.
What is the Price/Earnings (PE) ratio of ZENAS BIOPHARMA INC (ZBIO)?
ZENAS BIOPHARMA INC (ZBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.97).
What is the Short Interest ratio of ZENAS BIOPHARMA INC (ZBIO) stock?
The outstanding short interest for ZENAS BIOPHARMA INC (ZBIO) is 15.86% of its float. Check the ownership tab for more information on the ZBIO short interest.
ZBIO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ZBIO.
ZBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZBIO. While ZBIO has a great health rating, there are worries on its profitability.
ZBIO Financial Highlights
Over the last trailing twelve months ZBIO reported a non-GAAP Earnings per Share(EPS) of -11.97. The EPS decreased by -1173.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.43% | ||
| ROE | -50.24% | ||
| Debt/Equity | 0 |
ZBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 89% to ZBIO. The Buy consensus is the average rating of analysts ratings from 13 analysts.